Complementary Alternative Cancer Therapies References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Isobe T, Herbst RS et al. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol. 2005 Jun;32(3):315-28.
  2. Ostoros G, Kovacs G et al. [New therapies for non-small cell lung cancer]. Orv Hetil. 2005 May 22;146(21):1135-41.
  3. Ettinger DS. Non-small cell lung cancer treatment-related bone marrow toxicities. Semin Oncol. 2005 Apr;32(2 Suppl 3):81-5.
  4. Giraud P, Cosset JM. [Radiation toxicity to the heart: physiopathology and clinical data]. Bull Cancer. 2004 Nov 1;91 Suppl 3:147-53.
  5. Munden RF, Erasmus JJ et al. Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: an unusual CT appearance. AJR Am J Roentgenol. 2005 Apr;184(4):1091-5.
  6. Deng G, Cassileth BR. Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance. CA Cancer J Clin. 2005 Mar;55(2):109-16.
  7. Hann D, Baker F et al. Long-term breast cancer survivors' use of complementary therapies: perceived impact on recovery and prevention of recurrence. Integr Cancer Ther. 2005 Mar;4(1):14-20.
  8. Molassiotis A, Fernadez-Ortega P et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005 Apr;16(4):655-63.
  9. Deng G, Cassileth BR et al. Complementary therapies for cancer-related symptoms. J Support Oncol. 2004 Sep;2(5):419-26.
  10. Tindle HA, Davis RB, et al. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med. 2005 Jan-Feb;11(1):42-9.
  11. Yates JS, Mustian KM et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer. 2005 Feb 15.
  12. Pathak AK, Bhutani M et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005 Feb;24(1):16-21.
  13. Drisko JA, Chapman J, et al. The use of antioxidant therapies during chemotherapy.Gynecol Oncol. 2003 Mar;88(3):434-9. Review.
  14. Jatoi A, Daly BD et al. A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients. J Surg Oncol. 1998 Aug;68(4):231-6.
  15. Jatoi A, Williams B et al. Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005a Jul;49(1):77-84.
  16. Jatoi A, Williams BA et al. Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohort. Nutr Cancer. 2005b;51(1):7-12.
  17. Lamm DL, Riggs DR et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994 Jan;151(1):21-6.
  18. Tallberg T, Uusitalo R et al. Improvement of the recurrence-free interval using biological adjuvant therapy in uveal melanoma. Anticancer Res. 2000 May;20(3B):1969-75.
  19. Fleischauer AT, Simonsen N et al. Antioxidant supplements and risk of breast cancer recurrence and breast cancer-related mortality among postmenopausal women. Nutr Cancer. 2003;46(1):15-22.
  20. Kreienberg R. [Therapy of anthracycline-resistant metastatic breast carcinoma]. Schweiz Rundsch Med Prax. 1998 Apr 22;87(17):573-7.
  21. Christopoulou A. Chemotherapy in metastatic colorectal cancer. Tech Coloproctol. 2004 Nov;8 Suppl 1:s43-s46.
  22. Loffler TM, Korsten FW et al. [Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]. Dtsch Med Wochenschr. 1992 Jun 26;117(26):1007-13.
  23. Campbell MJ, Scott J et al. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May;91(2):163-71.
  24. Malmberg KJ, Lenkei R et al. A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res. 2002 Jun;8(6):1772-8.
  25. Lesperance ML, Olivotto IA et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat. 2002 Nov;76(2):137-43.
  26. Branda RF, Naud SJ et al. Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy--induced mucositis and neutropenia. Cancer. 2004 Sep 1;101(5):1058-64.
  27. Moss RW. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther. 2006 Mar;5(1):63-82.
  28. D'Andrea GM.Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005 Sep-Oct;55(5):319-21. Review.
  29. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park). 1999 Jul;13(7):1003-8.
  30. Mehta MP. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Semin Radiat Oncol. 1998 Oct;8(4 Suppl 1):14-6.
  31. Schwartz GN, Pendyala L et al. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer. 1998 Sep;34(10):1543-8.
  32. Spencer A, Horvath N et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005 May;35(10):971-7.
  33. Olver I, Keefe D et al. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna. Chemotherapy. 2005 May;51(2-3):142-6.
  34. Antman K, Crowley J et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276-85.
  35. Komaki R, Lee JS et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):46-9.
  36. Barber MD, Fearon KC et al.. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001b;40(2):118-24.
  37. Brown TT, Zelnik DL et al. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer. 2003;34(2-3):143-50.
  38. Park CH. Vitamin C in leukemia and preleukemia cell growth. Prog Clin Biol Res. 1988;259:321-30.
  39. Prasad KN, Kumar R. Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture. Nutr Cancer. 1996;26(1):11-9.
  40. Pandey M, Thomas BC. Rehabilitation of cancer patients. J Postgrad Med. 2001 Jan;47(1):62-5.
  41. Santiago-Palma J, Payne R. Palliative care and rehabilitation. Cancer. 2001 Aug 15;92(4 Suppl):1049-52.
  42. Cheville AL. Cancer rehabilitation. Semin Oncol. 2005 Apr;32(2):219-24.
  43. Fialka-Moser V, Crevenna R et al. Cancer rehabilitation: particularly with aspects on physical impairments. J Rehabil Med. 2003 Jul;35(4):153-62.
  44. Samuels N. [Acupuncture for cancer patients: why not?]. Harefuah. 2002 Jul;141(7):608-10, 666.
  45. Johnstone PA, Polston GR et al. Integration of acupuncture into the oncology clinic. Palliat Med. 2002 May;16(3):235-9.
  46. Elkins G, Marcus J et al. Can hypnosis reduce hot flashes in breast cancer survivors? A literature review. Am J Clin Hypn. 2004 Jul;47(1):29-42.
  47. Marcus J, Elkins G et al. The integration of hypnosis into a model of palliative care. Integr Cancer Ther. 2003 Dec;2(4):365-70.
  48. Stalpers LJ, da Costa HC et al. Hypnotherapy in radiotherapy patients: a randomized trial. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):499-506.
  49. Kim SD, Kim HS. Effects of a relaxation breathing exercise on fatigue in haemopoietic stem cell transplantation patients. J Clin Nurs. 2005 Jan;14(1):51-5.
  50. Fellowes D, Barnes K et al. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database Syst Rev. 2004;(2):CD002287.
  51. Hernandez-Reif M, Field T et al. Natural killer cells and lymphocytes increase in women with breast cancer following massage therapy. Int J Neurosci. 2005 Apr;115(4):495-510.
  52. Kohara H, Miyauchi T et al. Combined modality treatment of aromatherapy, footsoak, and reflexology relieves fatigue in patients with cancer. J Palliat Med. 2004 Dec;7(6):791-6.
  53. Shannahoff-Khalsa DS. Patient perspectives: Kundalini yoga meditation techniques for psycho-oncology and as potential therapies for cancer. Integr Cancer Ther. 2005 Mar;4(1):87-100.
  54. Christie W, Moore C. The impact of humor on patients with cancer. Clin J Oncol Nurs. 2005 Apr;9(2):211-8.
  55. Bennett MP, Zeller JM et al. The effect of mirthful laughter on stress and natural killer cell activity. Altern Ther Health Med. 2003 Mar;9(2):38-45.
  56. Berk LS, Felten DL et al. Modulation of neuroimmune parameters during the eustress of humor-associated mirthful laughter. Altern Ther Health Med. 2001 Mar;7(2):62-6.
  57. Takahashi K, Iwase M et al. The elevation of natural killer cell activity induced by laughter in a crossover designed study. Int J Mol Med. 2001 Dec;8(6):645-50.
  58. Felder BE. Hope and coping in patients with cancer diagnoses. Cancer Nurs. 2004 Jul;27(4):320-4.
  59. Watts S, Edgar L. Nucare, a coping skills training intervention for oncology patients and families: participants' motivations and expectations. Can Oncol Nurs J. 2004;14(2):84-95.
  60. Jones LW, Courneya KS et al. Association between exercise and quality of life in multiple myeloma cancer survivors. Support Care Cancer. 2004 Nov;12(11):780-8.
  61. Mustian KM, Katula JA et al. Tai Chi Chuan, health-related quality of life and self-esteem: a randomized trial with breast cancer survivors. Support Care Cancer. 2004 Dec;12(12):871-6.
  62. Dimeo FC, Thomas F et al. Effect of aerobic exercise and relaxation training on fatigue and physical performance of cancer patients after surgery. A randomised controlled trial. Support Care Cancer. 2004 Nov;12(11):774-9.
  63. Kendall AR, Mahue-Giangreco M et al. Influence of exercise activity on quality of life in long-term breast cancer survivors. Qual Life Res. 2005 Mar;14(2):361-71.
  64. Mock V, Frangakis C et al. Exercise manages fatigue during breast cancer treatment: A randomized controlled trial. Psychooncology. 2005 Jun;14(6):464-77.
  65. Stevinson C, Lawlor DA et al. Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes Control. 2004 Dec;15(10):1035-56.
  66. Thorsen L, Skovlund E et al. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol. 2005 Apr 1;23(10):2378-88.
  67. Dalal S, Bruera E. Dehydration in cancer patients: to treat or not to treat. J Support Oncol. 2004 Nov;2(6):467-79, 483.
  68. Bruera E, Sala R et al. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol. 2005 Apr 1;23(10):2366-71.
  69. Polycarpe E, Arnould L et al. Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer. 2004 Aug 10;111(1):131-7.
  70. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol. 2003 May;1(1):35-46.
  71. Morita T, Shima Y et al. Physician- and nurse-reported effects of intravenous hydration therapy on symptoms of terminally ill patients with cancer. J Palliat Med. 2004 Oct;7(5):683-93.
  72. Morita T, Hyodo I et al. Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol. 2005 Apr;16(4):640-7.
  73. Usharani K, Roy RK et al. Nutritional status of cancer patients given different treatment modalities. Int J Food Sci Nutr. 2004 Aug;55(5):363-9.
  74. Guo Y, Palmer JL et al. Nutritional status of cancer patients and its relationship to function in an inpatient rehabilitation setting. Support Care Cancer. 2005 Mar;13(3):169-75.
  75. Colasanto JM, Prasad P et al. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Huntingt). 2005 Mar;19(3):371-9.
  76. Hyltander A, Bosaeus I et al. Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. Clin Gastroenterol Hepatol. 2005 May;3(5):466-74.
  77. Hoda D, Jatoi A et al. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer. 2005 Feb 15;103(4):863-8.
  78. McKinlay AW. Nutritional support in patients with advanced cancer: permission to fall out? Proc Nutr Soc. 2004 Aug;63(3):431-5.
  79. Bahl M, Siu LL et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1127-36.
  80. Capra S, Ferguson M et al. Cancer: impact of nutrition intervention outcome--nutrition issues for patients. Nutrition. 2001 Sep;17(9):769-72.
  81. Read JA, Clarke SJ et al. Nutritional and anti-inflammatory strategies in the treatment of advanced colorectal cancer - a pilot study. Asia Pac J Clin Nutr. 2004;13(Suppl):S93.
  82. Tian J, Chen JS. Nutritional status and quality of life of the gastric cancer patients in Changle County of China. World J Gastroenterol. 2005 Mar 21;11(11):1582-6.
  83. Ravasco P, Monteiro-Grillo I et al. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005b Mar 1;23(7):1431-8.
  84. Ravasco P, Monteiro-Grillo I et al. Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005a Aug;27(8):659-68.
  85. Moskovitz DN, Kim YI. Does perioperative immunonutrition reduce postoperative complications in patients with gastrointestinal cancer undergoing operations? Nutr Rev. 2004 Nov;62(11):443-7.
  86. Ates E, Yilmaz S et al. Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). Acta Gastroenterol Belg. 2004 Jul;67(3):250-4.
  87. Farreras N, Artigas V et al. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr. 2005 Feb;24(1):55-65.
  88. Tsutsumi M, Ishikawa S et al. [PSA change and morbidity of prostate cancer after dietary intervention of low-fat and high-soybean-protein diet for patients with high serum PSA level]. Hinyokika Kiyo. 2004 Dec;50(12):847-51.
  89. Shaukat A, Scouras N et al. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol. 2005 Feb;100(2):390-4.
  90. Flood A, Peters U et al. Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):126-32.
  91. Sandler RS. Calcium supplements to prevent colorectal adenomas. Am J Gastroenterol. 2005 Feb;100(2):395-6.
  92. Campbell JK, Canene-Adams K et al. Tomato phytochemicals and prostate cancer risk. J Nutr. 2004 Dec;134(12 Suppl):3486S-92S.
  93. Jian L, Du CJ et al. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer. 2005 Mar 1;113(6):1010-4.
  94. Kucuk O, Sarkar FH et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood ). 2002 Nov;227(10):881-5.
  95. Nair S, Norkus EP et al. Serum and colon mucosa micronutrient antioxidants: differences between adenomatous polyp patients and controls. Am J Gastroenterol. 2001 Dec;96(12):3400-5.
  96. Nkondjock A, Ghadirian P et al. Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr. 2005 Mar;135(3):592-7.
  97. Huncharek M, Klassen H et al. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: a meta-analysis of 3,782 subjects from five observational studies. In Vivo. 2001 Jul;15(4):339-43.
  98. Toniolo P, Van Kappel AL et al. Serum carotenoids and breast cancer. Am J Epidemiol. 2001 Jun 15;153(12):1142-7.
  99. Schabath MB, Grossman HB et al. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec;134(12):3362-9.
  100. Slattery ML, Benson J et al. Carotenoids and colon cancer. Am J Clin Nutr. 2000 Feb;71(2):575-82.
  101. Aggarwal BB, Kumar A et al. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003 Jan;23(1A):363-98.
  102. Sharma RA, Euden SA et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847-54.
  103. Dorai T, Gehani N et al. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 2000 Aug;3(2):84-93.
  104. Dorai T, Dutcher JP et al. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004 Jun 15;60(1):1-17.
  105. Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol. 2004 Mar;35(3):301-7.
  106. Inano H, Onoda M et al. Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats. Carcinogenesis. 2000 Oct;21(10):1835-41.
  107. Das S. Garlic - a natural source of cancer preventive compounds. Asian Pac J Cancer Prev. 2002;3(4):305-11.
  108. Khanum F, Anilakumar KR et al. Anticarcinogenic properties of garlic: a review. Crit Rev Food Sci Nutr. 2004;44(6):479-88.
  109. Sengupta A, Ghosh S et al. Allium vegetables in cancer prevention: an overview. Asian Pac J Cancer Prev. 2004 Jul;5(3):237-45.
  110. Hsing AW, Chokkalingam AP et al. Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst. 2002 Nov 6;94(21):1648-51.
  111. Li H, Li HQ et al. An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum. Chin Med J (Engl ). 2004 Aug;117(8):1155-60.
  112. Oommen S, Anto RJ et al. Allicin (from garlic) induces caspase-mediated apoptosis in cancer cells. Eur J Pharmacol. 2004 Feb 6;485(1-3):97-103.
  113. Tanaka S, Haruma K et al. Effects of aged garlic extract (AGE) on colorectal adenomas: a double-blinded study. Hiroshima J Med Sci. 2004 Dec;53(3-4):39-45.
  114. Xu B, Monsarrat B et al. Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam Clin Pharmacol. 2004 Apr;18(2):171-80.
  115. Yang CS, Liao J et al. Inhibition of lung tumorigenesis by tea. Exp Lung Res. 2005 Jan;31(1):135-44.
  116. Seely D, Mills EJ et al. The Effects of Green Tea Consumption on Incidence of Breast Cancer and Recurrence of Breast Cancer: A Systematic Review and Meta-analysis. Integr Cancer Ther. 2005 Jun;4(2):144-55.
  117. Zhang M, Lee AH et al. Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer. 2004a Nov 10;112(3):465-9.
  118. Bonner MR, Rothman N et al. Green tea consumption, genetic susceptibility, PAH-rich smoky coal, and the risk of lung cancer. Mutat Res. 2005 Apr 4;582(1-2):53-60.
  119. Doss MX, Potta SP et al. Trapping of growth factors by catechins: a possible therapeutical target for prevention of proliferative diseases. J Nutr Biochem. 2005 May;16(5):259-66.
  120. Fujiki H. Green tea: Health benefits as cancer preventive for humans. Chem Rec. 2005;5(3):119-32.
  121. Martinez ME, Henning SM et al. Folate and colorectal neoplasia: relation between plasma and dietary markers of folate and adenoma recurrence. Am J Clin Nutr. 2004 Apr;79(4):691-7.
  122. Strohle A, Wolters M et al. Folic acid and colorectal cancer prevention: molecular mechanisms and epidemiological evidence (Review). Int J Oncol. 2005 Jun;26(6):1449-64.
  123. Shen H, Wei Q et al. Dietary folate intake and lung cancer risk in former smokers: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):980-6.
  124. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol. 2004b Feb;16(1):19-25.
  125. Anisimov VN. The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol. 2003 Jun;46(3):221-34.
  126. Sainz RM, Mayo JC et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005 Apr 1;63(1):29-43.
  127. Lissoni P, Chilelli M et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003 Aug;35(1):12-5.
  128. Shiu SY, Law IC et al. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res. 2003 Oct;35(3):177-82.
  129. Coleman MP, Reiter RJ. Breast cancer, blindness and melatonin. Eur J Cancer. 1992;28(2-3):501-3.
  130. Feychting M, Osterlund B et al. Reduced cancer incidence among the blind. Epidemiology. 1998 Sep;9(5):490-4.
  131. Combs GF, Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr. 2005 Feb;135(2):343-7.
  132. Mark SD, Qiao YL et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000 Nov 1;92(21):1753-63.
  133. Brooks JD, Metter EJ et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001 Dec;166(6):2034-8.
  134. Clark LC, Combs GF, Jr. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957-63.
  135. Duffield-Lillico AJ, Slate EH et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003 Oct 1b;95(19):1477-81.
  136. Vadgama JV, Wu Y et al. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000 May;20(3A):1391-414.
  137. Hehr T, Hoffmann W et al. [Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma]. Med Klin (Munich). 1997 Sep 15;92 Suppl 3:48-9.
  138. Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov 2;555(1-2):21-32.
  139. vis-Searles PR, Nakanishi Y et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005 May 15;65(10):4448-57.
  140. Clarke N, Germain P et al. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med. 2004 Nov 30;6(25):1-23.
  141. Khera P, Koo JY. A review of the chemopreventive and chemotherapeutic effects of topical and oral retinoids for both cutaneous and internal neoplasms. J Drugs Dermatol. 2005 Jul;4(4):432-46.
  142. Takai K, Okuno M et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology. 2005 Jan;48(1):39-45.
  143. Hercberg S, Galan P et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004 Nov 22;164(21):2335-42.
  144. Meyer F, Galan P et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005 Aug 20;116(2):182-6.
  145. Mooney LA, Madsen AM et al. Antioxidant vitamin supplementation reduces benzo(a)pyrene-DNA adducts and potential cancer risk in female smokers. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):237-42.
  146. Wright ME, Mayne ST et al. Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers. Am J Epidemiol. 2004 Jul 1;160(1):68-76.
  147. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-1688S.
  148. Kimlin MG, Schallhorn KA. Estimations of the human 'vitamin D' UV exposure in the USA. Photochem Photobiol Sci. 2004 Nov;3(11-12):1067-70.
  149. Ainsleigh HG. Beneficial effects of sun exposure on cancer mortality. Prev Med. 1993 Jan;22(1):132-40.
  150. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003 Nov;14(9):423-30.
  151. Studzinski GP, Moore DC. Sunlight--can it prevent as well as cause cancer? Cancer Res. 1995 Sep 15;55(18):4014-22.
  152. Hughes AM, Armstrong BK et al. Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int J Cancer. 2004 Dec 10;112(5):865-71.
  153. Agoston ES, Hatcher MA, et al. Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem. 2006 Jan;6(1):53-71. Review.
  154. Guyton KZ, Kensler TW et al. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003 Jul;61(7):227-38.
  155. Helzlsouer KJ, Huang HY et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000 Dec 20;92(24):2018-23.
  156. Woodson K, Tangrea JA et al. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst. 1999 Oct 20;91(20):1738-43.
  157. Jacobs EJ, Henion AK et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol. 2002 Dec 1;156(11):1002-10.
  158. Barnett KT, Fokum FD et al. Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res. 2002 Aug;106(2):292-8.
  159. Malafa MP, Fokum FD et al. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann Surg Oncol. 2002b Dec;9(10):1023-32.
  160. Malafa MP, Fokum FD et al. Vitamin E inhibits melanoma growth in mice. Surgery. 2002a Jan;131(1):85-91.
  161. Fleshner N, Al AR. Prostate cancer: chemoprevention update 2005. Can J Urol. 2005 Jun;12(3 Suppl):2-4.
  162. Lippman SM, Goodman PJ et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005 Jan 19;97(2):94-102.
  163. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev. 2003 Aug;8(3):303-18.
  164. Habu D, Shiomi S et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 2004 Jul 21;292(3):358-61.
  165. Woodson K, Triantos S et al. Long-term alpha-tocopherol supplementation is associated with lower serum vascular endothelial growth factor levels. Anticancer Res. 2002 Jan;22(1A):375-8.
  166. Furness MS, Robinson TP et al. Antiangiogenic agents: studies on fumagillin and curcumin analogs. Curr Pharm Des. 2005;11(3):357-73.
  167. Arbiser JL, Klauber N et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998 Jun;4(6):376-83.
  168. Dulak J. Nutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol. 2005 Mar;56 Suppl 1:51-69.
  169. Cooper R, Morre DJ et al. Medicinal benefits of green tea: part I. Review of noncancer health benefits. J Altern Complement Med. 2005 Jun;11(3):521-8.
  170. Jung YD, Ellis LM. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol. 2001 Dec;82(6):309-16.
  171. Albrecht M, Jiang W et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food. 2004;7(3):274-83.
  172. Vantyghem SA, Wilson SM et al. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res. 2005 Apr 15;65(8):3396-403.
  173. Ravindranath MH, Muthugounder S et al. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 2004;546:121-65.
  174. Mego M, Ebringer L et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I. Neoplasma. 2005;52(2):159-64.
  175. Garami M, Schuler D et al. Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. J Pediatr Hematol Oncol. 2004 Oct;26(10):631-5.
  176. Patya M, Zahalka MA et al. Allicin stimulates lymphocytes and elicits an antitumor effect: a possible role of p21ras. Int Immunol. 2004 Feb;16(2):275-81.
  177. Hassan ZM, Yaraee R et al. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int Immunopharmacol. 2003 Oct;3(10-11):1483-9.
  178. Tang Z, Sheng Z et al. [The preventing function of garlic on experimental oral precancer and its effect on natural killer cells, T-lymphocytes and interleukin-2]. Hunan Yi Ke Da Xue Xue Bao. 1997;22(3):246-8.
  179. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003 Sep;2(3):247-67.
  180. Suh SO, Kroh M et al. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med. 2002;30(4):483-94.
  181. Ahn WS, Kim DJ et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004 Jul;14(4):589-94.
  182. Gao Y, Zhou S et al. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
  183. Tsang KW, Lam CL, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med. 2003 Jun;97(6):618-24.
  184. Kodama N, Komuta K, et al. Can maitake MD-fraction aid cancer patients? Altern Med Rev. 2002 Jun;7(3):236-9. Review.
  185. Braga M, Gianotti L et al. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery. 2002 Nov;132(5):805-14.
  186. Song JX, Qing SH et al. Effect of parenteral nutrition with L-arginine supplementation on postoperative immune function in patients with colorectal cancer. Di Yi Jun Yi Da Xue Xue Bao. 2002 Jun;22(6):545-7.
  187. Bartsch C, Bartsch H. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol. 1999;467:247-64.
  188. Neri B, de L, V et al. Melatonin as biological response modifier in cancer patients. Anticancer Res. 1998 Mar;18(2B):1329-32.
  189. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci. 2000;917:560-7.
  190. Lissoni P, Malugani F et al. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
  191. Hernandez-Reif M, Ironson G et al. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. J Psychosom Res. 2004 Jul;57(1):45-52.
  192. Hidderley M, Holt M. A pilot randomized trial assessing the effects of autogenic training in early stage cancer patients in relation to psychological status and immune system responses. Eur J Oncol Nurs. 2004 Mar;8(1):61-5.
  193. Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage. 2004 Sep;28(3):244-9.
  194. Soden K, Vincent K et al. A randomized controlled trial of aromatherapy massage in a hospice setting. Palliat Med. 2004 Mar;18(2):87-92.
  195. Ohara-Hirano Y, Kaku T et al. Uterine cervical cancer: a holistic approach to mental health and it's socio-psychological implications. Fukuoka Igaku Zasshi. 2004 Aug;95(8):183-94.
  196. Cruciani RA, Dvorkin E et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004 Nov;1033:168-76.
  197. Collins KB, Thomas DJ. Acupuncture and acupressure for the management of chemotherapy-induced nausea and vomiting. J Am Acad Nurse Pract. 2004 Feb;16(2):76-80.
  198. Klein J, Griffiths P. Acupressure for nausea and vomiting in cancer patients receiving chemotherapy. Br J Community Nurs. 2004 Sep;9(9):383-8.
  199. Shin YH, Kim TI et al. Effect of acupressure on nausea and vomiting during chemotherapy cycle for Korean postoperative stomach cancer patients. Cancer Nurs. 2004 Jul;27(4):267-74.
  200. Gan TJ, Jiao KR et al. A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. Anesth Analg. 2004 Oct;99(4):1070-5, table.
  201. Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition. 2001a Sep;17(9):751-5.
  202. Fearon KC, Von Meyenfeldt MF et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003 Oct;52(10):1479-86.
  203. Bruera E, Strasser F et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003 Jan 1;21(1):129-34.
  204. Burns CP, Halabi S et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 2004 Jul 15;101(2):370-8.
  205. Ashikaga T, Bosompra K et al. Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer. 2002 Oct;10(7):542-8.
  206. McNeely ML, Magee DJ et al. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004 Jul;86(2):95-106.
  207. Mortimer PS. Therapy approaches for lymphedema. Angiology. 1997 Jan;48(1):87-91.
  208. Bruns F, Micke O et al. Current status of selenium and other treatments for secondary lymphedema. J Support Oncol. 2003 Jul;1(2):121-30.
  209. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005 Jun 1;293(21):2648-53.
  210. Jayne DG, Brown JM et al. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg. 2005 Jul 4.
  211. Turner SL, Adams K et al. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology. 1999 Jul;54(1):124-9.
  212. Molina JR, Barton DL et al. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf. 2005;28(5):401-16.
  213. Incrocci L, Hop WC et al. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. Urology. 2003a Jul;62(1):116-20.
  214. Incrocci L, Hop WC et al. [Favorable effect of sildenafil on erectile dysfunction in patients after radiotherapy for prostate cancer; randomised, double-blind, placebo-controlled crossover study]. Ned Tijdschr Geneeskd. 2003b Aug 30;147(35):1687-90.
  215. Lebret T, Herve JM et al. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. 2002 Jun;41(6):608-13.
  216. Ito T, Kawahara K et al. The effects of ArginMax, a natural dietary supplement for enhancement of male sexual function. Hawaii Med J. 1998 Dec;57(12):741-4.
  217. Ito TY, Trant AS et al. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001 Oct;27(5):541-9.
  218. Lau BH, Lau EW. Kyo-Green improves sexual dysfunction in men and women. Med Sci Monit. 2003 Feb;9(2):I12-I18.
  219. D'Agostini F, Bagnasco M et al. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol. 1998 Aug;13(2):217-24.
  220. De Leonardis V, Neri B, et al. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. Int J Clin Pharmacol Res. 1985;5(2):137-42.
  221. Cohen AJ, Menter A et al. Acupuncture: Role in Comprehensive Cancer Care--A Primer for the Oncologist and Review of the Literature. Integr Cancer Ther. 2005 Jun;4(2):131-43.
  222. Daniele B, Perrone F et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001 Jan;48(1):28-33.
  223. Savarese DM, Savy G et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003 Dec;29(6):501-13.
  224. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther. 2004 Dec;3(4):333-41.
  225. Wattanapitayakul SK, Chularojmontri L et al. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity. Basic Clin Pharmacol Toxicol. 2005 Jan;96(1):80-7.
  226. Majsterek I, Gloc E et al. A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res. 2005 May;38(4):254-63.
  227. Ahmed HH, Mannaa F et al. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg Med Chem. 2005 Mar 1;13(5):1847-57.
  228. Balli E, Mete UO et al. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopathol. 2004 Oct;19(4):1101-8.
  229. Levitsky J, Hong JJ et al. Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum. 2003 May;46(5):679-82.
  230. Vorotnikova E, Tries M et al. Retinoids and TIMP1 prevent radiation-induced apoptosis of capillary endothelial cells. Radiat Res. 2004 Feb;161(2):174-84.
  231. Argyriou AA, Chroni E et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology. 2005 Jan 11;64(1):26-31.
  232. Pace A, Savarese A et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003 Mar 1;21(5):927-31.
  233. Boon H, Wong J. Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother. 2004 Dec;5(12):2485-501.
  234. Sharma SS, Gupta YK. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J Ethnopharmacol. 1998 Aug;62(1):49-55.
  235. Manusirivithaya S, Sripramote M et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004 Nov;14(6):1063-9.
  236. Bokemeyer C, Fels LM et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer. 1996 Dec;74(12):2036-41.
  237. Mori K, Kondo T et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003 May;51(5):403-6.
  238. Taixiang W, Munro AJ et al. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005;(1):CD004540.
  239. Portakal O, Ozkaya O, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000 Jun;33(4):279-84.
  240. Bandy B, Davison AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med. 1990;8(6):523-39. Review.
  241. Iarussi D, Auricchio U, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med. 1994;15 Suppl:s207-s212.